Haleon (HLN) Projected to Post Quarterly Earnings on Thursday

Key Points

• Haleon (NYSE:HLN) is set to announce its quarterly earnings on Thursday, August 7th, with analysts expecting earnings of $0.24 per share and revenue of $7.48 billion.
• The company has received mixed ratings from analysts, with a recent upgrade to a "strong-buy" by BNP Paribas and an average price target of $12.33.
• Several large investors, such as Geneos Wealth Management Inc. and AQR Capital Management LLC, have increased their stakes in Haleon, indicating growing institutional interest.

Haleon (NYSE:HLN - Get Free Report) is anticipated to post its H1 2025 quarterly earnings results before the market opens on Thursday, August 7th. Analysts expect Haleon to post earnings of $0.24 per share and revenue of $7.48 billion for the quarter.

Haleon Price Performance

Shares of NYSE HLN traded down $0.16 during mid-day trading on Monday, hitting $9.51. 7,058,203 shares of the stock traded hands, compared to its average volume of 13,289,573. The company has a debt-to-equity ratio of 0.53, a current ratio of 0.98 and a quick ratio of 0.78. Haleon has a twelve month low of $8.86 and a twelve month high of $11.42. The company has a market cap of $42.70 billion, a PE ratio of 24.35, a price-to-earnings-growth ratio of 2.79 and a beta of 0.23. The firm has a 50 day simple moving average of $10.37 and a two-hundred day simple moving average of $10.20.

Institutional Trading of Haleon

A number of institutional investors have recently made changes to their positions in HLN. Geneos Wealth Management Inc. lifted its holdings in Haleon by 33.0% in the first quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company's stock worth $50,000 after buying an additional 1,203 shares during the period. Focus Partners Wealth lifted its position in Haleon by 7.6% during the first quarter. Focus Partners Wealth now owns 73,106 shares of the company's stock valued at $752,000 after buying an additional 5,178 shares during the period. AQR Capital Management LLC lifted its position in Haleon by 22.5% during the 1st quarter. AQR Capital Management LLC now owns 96,323 shares of the company's stock valued at $991,000 after acquiring an additional 17,720 shares during the period. Finally, Brighton Jones LLC purchased a new position in Haleon in the 4th quarter worth about $187,000. Hedge funds and other institutional investors own 6.67% of the company's stock.

Analyst Ratings Changes

HLN has been the topic of a number of recent analyst reports. Wall Street Zen lowered Haleon from a "buy" rating to a "hold" rating in a research note on Saturday, July 12th. Barclays reiterated an "overweight" rating on shares of Haleon in a report on Tuesday, May 6th. Morgan Stanley upgraded shares of Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 price objective for the company in a research note on Friday, May 9th. BNP Paribas Exane upgraded shares of Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 price objective for the company in a research note on Tuesday, May 27th. Finally, BNP Paribas raised Haleon to a "strong-buy" rating in a research report on Tuesday, May 27th. Six analysts have rated the stock with a hold rating, four have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Haleon presently has an average rating of "Moderate Buy" and a consensus price target of $12.33.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.